Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13158074 | 1.00 | KDM4E (0.45) | KDM4ENPSR1ALDH1A1LMNARECQL | |
| SCHEMBL13158093 | 0.89 | ALDH1A1 (0.49) | KDM4ENPSR1ALDH1A1LMNARECQL | |
| SCHEMBL3107629 | 0.89 | ALDH1A1 (0.49) | KDM4ENPSR1ALDH1A1LMNARECQL | |
| SCHEMBL3093260 | 0.83 | GRIN2B (0.57) | NPSR1ALDH1A1KMT2ADRD2DRD3 | |
| SCHEMBL13157902 | 0.83 | GRIN2B (0.57) | NPSR1ALDH1A1KMT2ADRD2DRD3 | |
| SCHEMBL13158054 | 0.82 | HRH4 (0.44) | KDM4EALDH1A1DPP4DRD2DRD3 | |
| SCHEMBL3098496 | 0.82 | HRH4 (0.44) | KDM4EALDH1A1DPP4DRD2DRD3 | |
| SCHEMBL13158059 | 0.80 | RAB9A (0.54) | KDM4EALDH1A1DPP4DRD4HSD17B10 | |
| SCHEMBL3108214 | 0.80 | RAB9A (0.54) | KDM4EALDH1A1DPP4DRD4HSD17B10 | |
| SCHEMBL3109764 | 0.78 | F10 (0.50) | KDM4EALDH1A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399455-B2 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100234356-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234356-A1 | COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS | ACKR3, CCR5, CXCR2 | KDM4E 4629/4885NPSR1 100/4885ALDH1A1 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.